The DIAPH3 Knockout AGS Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal population of AGS gastric adenocarcinoma cells with targeted disruption of the DIAPH3 gene. This heterogeneous knockout model enables loss-of-function studies in a human epithelial context, capturing a spectrum of genetic alterations that reflect tumor heterogeneity. The polyclonal format circumvents clonal artifacts and offers a robust system for investigating DIAPH3-dependent cellular processes.
The AGS cell line, originating from a human gastric adenocarcinoma, grows as an adherent epithelial monolayer and serves as a standard model for studying gastric cancer pathogenesis. It is particularly suited for examining actin cytoskeletal dynamics, cell adhesion, and transepithelial migration. AGS cells retain functional adhesion junctions and respond to growth factor cues, providing a physiologically relevant host for investigating DIAPH3’s role in epithelial homeostasis and malignant transformation.
DIAPH3 encodes a formin protein that nucleates and elongates unbranched actin filaments downstream of Rho GTPases. It is activated by RhoA, Rac1, and Cdc42, and integrates signals from growth factor receptors like EGFR. DIAPH3 interacts with profilin and the Arp2/3 complex to regulate actin polymerization and associates with microtubule plus-end tracking proteins EB1 and CLIP-170, linking actin and microtubule networks. Key signaling axes include RhoA>DIAPH3>stress fiber formation, Rac1>DIAPH3>lamellipodia extension, and Cdc42>DIAPH3>filopodia assembly, which collectively control cell morphology, adhesion, and migration.
In gastric cancer, DIAPH3 is critical for actin-driven cell protrusion and invasion. Knockout in AGS cells impairs lamellipodia and filopodia formation, reducing cell motility and the capacity for matrix invasion. This model is particularly valuable for mechanistically dissecting how DIAPH3 contributes to metastatic dissemination and for evaluating its role in epithelial-to-mesenchymal-like transitions. The epithelial background also allows study of DIAPH3’s impact on junctional stability and collective cell migration, relevant to tumor progression.
Typical experiments include wound healing and Transwell invasion assays to quantify migration and invasiveness, and cell adhesion assays to measure substrate attachment. Immunofluorescence for F-actin reveals cytoskeletal organization, while Western blotting confirms DIAPH3 disruption and assesses downstream targets such as SRF transcriptional activity. These applications support drug discovery efforts targeting cytoskeletal regulators in gastric cancer. For more details, please contact Ascent Research.
